GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Selpercatinib (Retevmo), oral capsule

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Retevmo - labeled renal guidance

Product / population
Selpercatinib (Retevmo), oral capsule
Renal method
MDRD eGFR, mL/min as printed in this label
Source revision
DailyMed SPL version 25, posted Sep 14, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Retevmo - product and source limitations

Use the renal method and units printed in this label. Confirm the prescribed tablet or capsule.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Retevmo - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Selpercatinib (Retevmo), oral capsule

Renal method: MDRD eGFR, mL/min as printed in this label
Source date: DailyMed SPL version 25, posted Sep 14, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

The source specifies usual selpercatinib dosing for MDRD eGFR 15-89 mL/min. An ESRD dose has not been established. Use the renal method and units printed in this label. Confirm the prescribed tablet or capsule.

RDM74-retevmo-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828
Retrieved
2026-11-07
Renal-function method
MDRD eGFR, mL/min as printed in this label
Source date/version
DailyMed SPL version 25, posted Sep 14, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
48dc9a63b011a1bfc9471faf7027d298427f06b8a12635593812f66b1c5eed47

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-retevmo&s1=RDM74-retevmo-official&h1=36989328e11461c9f6ed6bc2991fb4f95c484ff06625a55b903471801dfebf53

Top